The short version for men on online TRT
Online-only testosterone therapy currently rests on a temporary federal rule, and that rule now runs through December 31, 2026. Because testosterone is a controlled substance, federal law normally requires at least one in-person medical evaluation before a clinician can start it through telemedicine. The DEA has suspended that requirement since 2020 through a series of extensions.
If you started TRT entirely by video and have never been examined in person by the clinician who manages it, your care depends on those extensions. If you have had at least one in-person visit with that clinician, the federal limits on starting controlled medicines remotely no longer apply to that relationship. The rest of this article explains why, what could change, and how to make sure you do not end up with a gap in treatment.
Why testosterone falls under DEA telemedicine rules
Testosterone is a Schedule III controlled substance under the Controlled Substances Act. The Kyzatrex label, like every testosterone label, states that classification in its section on abuse and dependence. That puts testosterone in the same regulatory family as other controlled medicines when it comes to remote care.
The relevant law is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. As the DEA summarizes it in the Federal Register notice for the fourth extension, a practitioner may remotely issue controlled substances only after at least one in-person medical evaluation, subject to a handful of exceptions. Once that single in-person evaluation has happened, the specific Ryan Haight requirements stop applying to that practitioner and patient, however much time passes and even if the visit was for a different concern.
Two details are worth underlining:
- The rule follows the practitioner. An in-person exam by one clinician does not automatically cover a different clinician who later takes over your care.
- State rules still apply. Meeting the federal requirement does not replace California’s own standards for evaluating patients.
Where the flexibilities stand in October 2026
The temporary rules have been extended four times. Here is the timeline from the DEA’s own notices.
| Date | What happened |
|---|---|
| March 2020 | DEA grants pandemic exceptions allowing controlled substances by audio-video telemedicine without a prior in-person visit |
| May 2023 | First temporary rule extends the exceptions as the public health emergency ends |
| October 2023 | Second extension, through December 31, 2024 |
| November 2024 | Third extension, through December 31, 2025 |
| January 2025 | DEA proposes a permanent special registration system for telemedicine |
| December 31, 2025 | Fourth extension, effective January 1 through December 31, 2026 |
The special registration proposal would let registered clinicians start controlled medicines by telemedicine without an in-person visit, with extra recordkeeping and reporting requirements. The DEA said it received more than 6,475 comments on it and extended the current flexibilities to give itself time to finalize a rule. As of October 8, 2026, no final special registration rule has been published, and no fifth extension has been announced.
What an in-person requirement would change for patients
If the flexibilities end without a replacement, the impact depends on how your care began. The table sketches the main situations.
| Your situation | What a return to the in-person rule would mean |
|---|---|
| Started TRT by video, never seen in person by that clinician | An in-person evaluation would generally be needed before testosterone could continue remotely |
| Seen in person at least once by the clinician managing TRT | No change to that relationship under the Ryan Haight Act |
| Switching to a new clinician or clinic | The new clinician would need an in-person evaluation, or another exception, to manage testosterone remotely |
| Travelling or living in another state | State licensing rules apply on top of federal rules |
The first group is the one most exposed to a so-called telemedicine cliff. The risk is not that testosterone becomes unavailable. It is that men discover in December that their next refill now requires a visit nobody scheduled.
How to avoid a gap in treatment
Planning ahead costs little. Stopping testosterone abruptly can bring back the symptoms that led you to start, and running short is when some men are tempted toward unregulated sources, which carry their own risks covered in our answer on self-sourced testosterone.
A short checklist:
- Find out whether you have ever had an in-person evaluation with the clinician who manages your testosterone. If you are not sure, ask.
- Know your refill timing. Map out when your supply runs out in relation to December 31, 2026.
- Get your records together: recent labs, your current dose and schedule, and any side effects or dose changes.
- Schedule early. An in-person visit in October or November is easier to arrange than one in the last week of December.
- If you are moving your care, overlap rather than stop. Our guide to switching TRT clinics without a gap walks through the order of steps.
A new evaluation is also a chance to check the basics. The Endocrine Society’s 2026 statement emphasizes accurate diagnosis on at least two early-morning tests and ongoing monitoring once therapy starts. If your original diagnosis rested on a single test, a fresh look at the numbers is worth having.
How Ultimate Male fits these rules
Every testosterone evaluation at Ultimate Male starts in person, at our San Gabriel clinic (Tuesday, Thursday and Friday) or our Downey clinic (by appointment). Blood is drawn on site the same day, results return in 24 to 48 hours, and your consultation with a PA-C or MD happens face to face. That in-person evaluation is the visit the Ryan Haight Act asks for, so the outcome of the federal extensions does not decide whether your follow-up care can continue.
If you are currently on a remote-only program and want a local clinician before the deadline, our TRT transfer page lists the records to bring. Transferring is still an evaluation rather than an automatic continuation of your current dose: the provider reviews your history and labs before recommending a plan. For background on the full range of options, see testosterone therapy at Ultimate Male or our comparison of online TRT and in-person care.
